Suppr超能文献

中性粒细胞弹性蛋白酶及其抑制剂在呼吸系统疾病中的作用研究进展

Research progress on the effect of neutrophil elastase and its inhibitors in respiratory diseases.

作者信息

Liang Cheng-Cheng, Zhao Ji, Zhang Yan-Qiu, Chen Jian, Wang Yong

机构信息

Department of Intensive Care Unit, Huaibei Miners General Hospital, China.

出版信息

J Int Med Res. 2025 Jun;53(6):3000605251352789. doi: 10.1177/03000605251352789. Epub 2025 Jun 28.

Abstract

Neutrophil elastase is a serine protease secreted by neutrophils that plays a crucial role in the onset and progression of various respiratory diseases. The imbalance between neutrophil elastase and its endogenous inhibitors can contribute to the onset and progression of respiratory diseases such as chronic obstructive pulmonary disease, cystic fibrosis, bronchiectasis, and acute respiratory distress syndrome. The excessive release of neutrophil elastase contributes to multiple pathophysiological processes, such as disruption of the alveolar-capillary barrier, oxidative stress and inflammatory responses, autophagy, and apoptosis. The use of neutrophil elastase as a biomarker in disease assessment and prognosis prediction as well as the potential of neutrophil elastase inhibitors in clinical treatment have shown broad application prospects. Neutrophil elastase inhibitors have certain limitations such as off-target effects, poor lung bioavailability, cost considerations, and variability in patient responses. This article reviews the literature on neutrophil elastase and its inhibitors in the field of respiratory diseases, aiming to provide new insights into the diagnosis and treatment of related respiratory diseases.

摘要

中性粒细胞弹性蛋白酶是中性粒细胞分泌的一种丝氨酸蛋白酶,在多种呼吸系统疾病的发生和发展中起关键作用。中性粒细胞弹性蛋白酶与其内源性抑制剂之间的失衡可导致慢性阻塞性肺疾病、囊性纤维化、支气管扩张和急性呼吸窘迫综合征等呼吸系统疾病的发生和发展。中性粒细胞弹性蛋白酶的过度释放会导致多种病理生理过程,如肺泡-毛细血管屏障破坏、氧化应激和炎症反应、自噬和凋亡。将中性粒细胞弹性蛋白酶用作疾病评估和预后预测的生物标志物以及中性粒细胞弹性蛋白酶抑制剂在临床治疗中的潜力已显示出广阔的应用前景。中性粒细胞弹性蛋白酶抑制剂存在一定局限性,如脱靶效应、肺部生物利用度差、成本因素以及患者反应的变异性。本文综述了呼吸系统疾病领域中关于中性粒细胞弹性蛋白酶及其抑制剂的文献,旨在为相关呼吸系统疾病的诊断和治疗提供新的见解。

相似文献

1
Research progress on the effect of neutrophil elastase and its inhibitors in respiratory diseases.
J Int Med Res. 2025 Jun;53(6):3000605251352789. doi: 10.1177/03000605251352789. Epub 2025 Jun 28.
2
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
5
Neutrophil elastase in bronchiectasis.
Respir Res. 2017 Dec 19;18(1):211. doi: 10.1186/s12931-017-0691-x.
7
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
8
p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics.
Cell Commun Signal. 2023 Nov 2;21(1):314. doi: 10.1186/s12964-023-01337-4.

本文引用的文献

3
Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of ALI/ARDS patients with COVID-19.
Heliyon. 2024 Aug 20;10(17):e36337. doi: 10.1016/j.heliyon.2024.e36337. eCollection 2024 Sep 15.
4
Neutrophil Extracellular Traps and Respiratory Disease.
J Clin Med. 2024 Apr 19;13(8):2390. doi: 10.3390/jcm13082390.
6
What the future holds: cystic fibrosis and aging.
Front Med (Lausanne). 2024 Jan 8;10:1340388. doi: 10.3389/fmed.2023.1340388. eCollection 2023.
7
Human neutrophil elastase inhibitors: Classification, biological-synthetic sources and their relevance in related diseases.
Fundam Clin Pharmacol. 2024 Feb;38(1):13-32. doi: 10.1111/fcp.12946. Epub 2023 Aug 23.
8
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.
Eur Respir J. 2023 Apr 1;61(4). doi: 10.1183/13993003.00239-2023. Print 2023 Apr.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验